The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Lisitsyn M.P.

Evdokimov Moscow State University of Medicine and Dentistry

Zaremuk A.M.

Evdokimov Moscow State University of Medicine and Dentistry

Lisitsyna E.M.

Guta Clinic

Atlukhanov R.Ya.

Centrosoyuz Hospital

Application of platelet-rich autoplasma in the treatment of gonarthrosis

Authors:

Lisitsyn M.P., Zaremuk A.M., Lisitsyna E.M., Atlukhanov R.Ya.

More about the authors

Journal: Endoscopic Surgery. 2020;26(6): 49‑62

Read: 5716 times


To cite this article:

Lisitsyn MP, Zaremuk AM, Lisitsyna EM, Atlukhanov RYa. Application of platelet-rich autoplasma in the treatment of gonarthrosis. Endoscopic Surgery. 2020;26(6):49‑62. (In Russ.)
https://doi.org/10.17116/endoskop20202606149

References:

  1. Marx RE, Carlson ER, Eichstaedt RM. Platelet-rich plasma — Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638-646. 
  2. Bennell K, Hunter D, Paterson K. Platelet-rich plasma for the management of hip and knee osteoarthritis. Curr Rheumatol Rep. 2017;19:24.  https://doi.org/10.1007/s11926-017-0652-x.
  3. Foster T, Puskas B, Mandelbaum B, Gerhardt M, Rodeo S. Platelet-rich plasma. Am J Sports Med. 2009;37:2259-2272. https://doi.org/10.1177/0363546509349921.
  4. Whitney K, Liebowitz A, Bolia I, Chahla J, Ravuri S, Evans T. Current perspectives on biological approaches for osteoarthritis. Ann N Y Acad Sci. 2017;1410:26-43.  https://doi.org/10.1111/nyas.13554.
  5. Sundman E, Cole B, Karas V, Della Valle C, Tetreault M, Mohammed H. The anti-in flammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2013;42:35-41.  https://doi.org/10.1177/0363546513507766.
  6. Andia I: Platelet-rich plasma biology; in Alves R, Grimalt R (eds): Clinical Indications and Treatment Protocols with Platelet-Rich Plasma in Dermatology. Barcelona, Ediciones Mayo, 2016.
  7. Matras H. Die Wirkungen verschiedener Fibrin proparate auf Kontinuitat-strennungen der Rattenhaut. Osterr Z Stomatol. 1970;67:338-359. 
  8. Schulz V, Kochsiek K, Kostering H, Ch Walther. The preparation of platelet-rich plasma for platelet counts and tests of platelet function (author’s transl). Z Klin Chem Klin Biochem. 1971;9:324-328. 
  9. Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B: Rev. 2008;14:249-258. 
  10. Rosenthal AR, Egbert PR, Harbury C, Hopkins JL, Rubenstein E. Use of platelet-fibrinogen-thrombin mixture to seal experi mental penetrating corneal wounds. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978;207:111-115. 
  11. Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant? Transfusion. 1990;30:741-747. 
  12. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic non healing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;04:322-330. 
  13. Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg. 1997;55:1294-1299.
  14. Dohan DM, Choukroun J, Diss A. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e37-44. 
  15. Dohan DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L- PRF). Trends Biotechnol. 2009;27:158-167. 
  16. Dohan DM, Choukroun J, Diss A. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e51-55. 
  17. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009;27:63-69. 
  18. Everts PA, Hoffmann J, Weibrich G. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfus Med. 2006;16:363-368. 
  19. Everts PA, van Zundert A, Schonberger JP, Devilee RJ, Knape JT. What do we use: platelet-rich plasma or platelet leukocyte gel? J Biomed Mater Res A. 2008;85:1135-1136.
  20. Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, Cieslik T. Why the platelet-rich gel has antimicrobial activity? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:303-305; author reply 305-306. 
  21. Cieslik-Bielecka A, Bielecki T, Gazdzik TS, Arendt J, Krol W, Szczepanski T. Autologous platelets and leukocytes can improve healing of infected high-energy soft tissue injury. Transfus Apher Sci. 2009;41:9-12. 
  22. Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol. 2012;13:1185-1195.
  23. Dohan Ehrenfest DM, Bielecki T, Del Corso M, Inchingolo F, Sammartino G. Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. J Biomed Mater Res A. 2010;95:1280-1282.
  24. Dohan Ehrenfest DM, Bielecki T, Jimbo R. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012;13:1145-1152.
  25. Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun’s platelet-rich fibrin clot and membrane. J Periodontol. 010;81:546-555. 
  26. Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28:4551-4560.
  27. Dohan Ehrenfest DM, Bielecki T, Del Corso M, Inchingolo F, Sammartino G. Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. J Biomed Mater Res A. 2010;95:1280-1282.
  28. Everts PA, Hoffmann J, Weibrich G, Mahoney CB, Schonberger JPAM. Differences in Platelet Growth Factor Release and Leucocyte Kinetics during Autologous Platelet Gel Formation. Transfus Med. 2006;16: 363-368. 
  29. Everts PA, Hoogbergen MM, Weber TA, Devilee RJ, van Monftort G, de Hingh IH. Is the use of autologous platelet-rich plasma gels in gynecologic, cardiac, and general, reconstructive surgery beneficial? Curr Pharm Biotechnol. 2012;13:1163-1172.
  30. Yuan T, Guo SC, Han P, Zhang CQ, Zeng BF. Applications of leukocyte- and platelet-rich plasma (L-PRP) in trauma surgery. Curr Pharm Biotechnol. 2012;13:1173-1184.
  31. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158-167. 
  32. Dohan DM, Choukroun J, Diss A. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e37-44. 
  33. Del Corso M, Vervelle A, Simonpieri A. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. Curr Pharm Biotechnol. 2012;13:1207-1230.
  34. Simonpieri A, Del Corso M, Vervelle A. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. Curr Pharm Biotechnol. 2012;13:1231-1256.
  35. Del Corso M, Dohan Ehrenfest DM. Immediate implantation andperi-implant Natural Bone Regeneration (NBR) in the severely resorbed posterior mandible using Leukocyte- and Platelet-Rich Fibrin (L-PRF): a 4-year follow-up. Poseido. 2013;1:109-116. 
  36. Dohan Ehrenfest DM, Sammartino G, Shibli JA, Wang HL, Zou DR, Bernard JP. Guidelines for the publication of articles related to platelet concentrates (Platelet-Rich Plasma — PRP, or Platelet-Rich Fibrin — PRF): the international classification of the POSEIDO. Poseido. 2013;1:17-27. 
  37. Toeroek R, Dohan Ehrenfest DM. The concept of Screw-Guided Bone Regeneration (S- GBR). Part 2: S-GBR in the severely resorbed preimplant posterior mandible using bone xenograft and Leukocyte- and Platelet-Rich Fibrin (L-PRF): a 5-year follow-up. Poseido. 2013;1:85-92. 
  38. Zumstein MA, Berger S, Schober M. Leukocyte- and platelet-rich fibrin (L-PRF) for long-term delivery of growth factor in rotator cuff repair: review, preliminary results and future directions. Curr Pharm Biotechnol. 2012;13:1196-1206.
  39. Zumstein MA, Bielecki T, Dohan Ehrenfest DM. The Future of Platelet Concentrates in Sports Medicine: Platelet-Rich Plasma, Platelet-Rich Fibrin, and the Impact of Scaffolds and Cells on the Long-term Delivery of Growth Factors. Operative Techniques Sports Med. 2011;19:190-197. 
  40. Yuan T, Guo SC, Han P, Zhang CQ, Zeng BF. Applications of leukocyte- and platelet- rich plasma (L-PRP) in trauma surgery. Curr Pharm Biotechnol. 2012;13:1173-1184.
  41. Dohan Ehrenfest DM, Bielecki T, Mishra A. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol. 2012;13:1131-1137.
  42. Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol. 2012;13:1185-1195.
  43. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone. 2004;34:665-671. 
  44. DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012;28:998-1009.
  45. Dohan Ehrenfest DM. How to optimize the preparation of leukocyte- and platelet-rich fibrin (L-PRF, Choukroun’s technique) clots and membranes: introducing the PRF Box. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:275-278; author reply 278-280. 
  46. Cieslik-Bielecka A, Choukroun J, Odin G, Dohan Ehrenfest DM. L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. Curr Pharm Biotechnol. 2012;13:1266-1277.
  47. Andia I, Maffulli N. Platelet-rich plasma for muscle injury and tendinopathy. Sports Med Arthrosc. 2013;21:191-198. 
  48. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013;9:721-730. 
  49. Bielecki T, Dohan Ehrenfest DM, Everts PA, Wiczkowski A. The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives. Curr Pharm Biotechnol. 2012;13:1153-1162.
  50. Moojen DJ, Everts PA, Schure RM. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008;26:404-410. 
  51. Dohan Ehrenfest DM. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscl, Ligament Tend J. 2014;4(1):3-9. 
  52. Michelson AD. Platelets. 3rd ed. San Diego: Elsevier/Academic Press; 2013.
  53. Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol. 2006;133:251-258. 
  54. De Gaetano G, Cerletti C. Platelet adhesion and aggregation and fibrin formation in flowing blood: a historical contribution by Giulio Bizzozero. Platelets. 2002;13(2):85-89. 
  55. Sharathkumar AA, Shapiro A. Platelet function disorders. Second Edition Indiana Hemophilia and Thrombosis Center Indianapolis, U.S.A. 
  56. Scherer SS, Tobalem M, Vigato E. Non activated versus thrombin-activated platelets on wound healing and fibroblast-to-myofibroblast differentiation in vivo and in vitro. Plast Reconstr Surg. 129(1):46-54. 
  57. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177-189. 
  58. Agata H, Asahina I, Yamazaki Y, Uchida M, Shinohara Y, Honda MJ, Kagami H, Ueda M. Effective bone engineering with periosteum-derived cell. J Dental Res. 2007;86(1):79-83. 
  59. Even J, Eskander M, Kang J. Bone morphogenetic protein in spine surgery: current and future uses. J Am Acad Orthop Surg. 2012;20:547-552. 
  60. Akeda K, An HS, Okuma M. Platelet-rich plasma stimulates porcine articular chondrocyte proliferation and matrix biosynthesis. Osteoarthritis Cartil. 2006;14(12):1272-1280.
  61. Pereira RC, Scaranari M, Benelli R. Dual effect of platelet lysate on human articular cartilage: a maintenance of chondrogenic potential and a transient proinflammatory activity followed by an inflammation resolution. Tissue Eng Part A. 2013;19(11-12):1476-1488.
  62. Park SI, Lee HR, Kim S. Time sequential modulation in expression of growth factors from platelet-rich plasma (PRP) on the chondrocyte cultures. Mol Cell Biochem. 2012;361(1-2):9-17. 
  63. Yang SY, Ahn ST, Rhie JW. Platelet supernatant promotes proliferation of auricular chondrocytes and formation of chondrocyte mass. Ann Plast Surg. 2000;44(4):405-411. 
  64. Spreafico A, Chellini F, Frediani B. Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. J Cell Biochem. 2009;108(5):1153-1165.
  65. Gaissmaier C, Fritz J, Krackhardt T. Effect of human platelet supernatant on proliferation and matrix synthesis of human articular chondrocytes in monolayer and three-dimensional alginate cultures. Biomaterials. 2005;26(14):1953-1960.
  66. Sundman EA, Cole BJ, Karas V. Theantiinflammatory and matrix restorative mechanisms of platelet rich plasma in osteoarthritis. Am J Sports Med. 2014;42(1):35-41. 
  67. Anitua E, Sanchez M, Nurden AT. Plateletreleased growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology (Oxford). 2007;46(12):1769-1772.
  68. Yin Z, Yang X, Jiang Y. Platelet-rich plasma combined with agarose as a bioactive scaffold to enhance cartilage repair: an in vitro study. J Biomater. 2013;28(7):1039-1050.
  69. Mifune Y, Matsumoto T, Takayama K. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthritis Cartil. 2013;21(1);175-185. 
  70. van Buul GM, Koevoet WL, Kops N. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med. 2011;39(11):2362-2370.
  71. Bendinelli P, Matteucci E, Dogliotti G. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol. 2010;225(3):757-766. 
  72. Wu CC, Chen WH, Zao B. Regenerative potentialsof platelet-rich plasma enhanced by collagen in retrieving proinflammatory cytokine-inhibited chondrogenesis. Biomaterials. 2011;32(25):5847-5854.
  73. Lee HR, Park KM, Joung YK. Platelet rich plasma loaded hydrogel scaffold enhances chondrogenic differentiation and maturation with up-regulation of CB1 and CB2. J Control Release. 2012;159(3);332-337. 
  74. Chakkalakal JV, Jones KM, Basson MA, Brack AS. The aged niche disrupts muscle stem cell quiescence. Nature. 2012;490:355-360. 
  75. Moussa M, Lajeunesse D, Hilal G, el Atat O, Haykal G, Serhal R. Platelet rich plasma (PRP) induces chondroprotection via increasing autophagy, anti-inflammatory markers, and decreasing apoptosis in human osteoarthritic cartilage. Exp Cell Res. 2017;352:146-156. 
  76. Garcia-Prat L, Martinez-Vicente M, Perdiguero E. Autophagy maintains stemness by preventing senescence. Nature. 2016;529:37-42. 
  77. Laver L, Marom N, Dnyanesh L. PRP for Degenerative Cartilage Disease: A Systematic Review of Clinical Studies. Cartilage. 2017;8(4):341-364. 
  78. Duymus TM, Mutlu S, Dernek B, Komur B, Aydogmus S, Kesiktas FN. Choice of intra-articular injection in treatment of knee osteoarthritis: Platelet-rich plasma, hyaluronic acid or ozone options [published online April 7, 2016]. Knee Surg Sports Traumatol Arthrosc. https://doi.org/10.1007/s00167-016-4110-5.
  79. Sanchez M, Fiz N, Azofra J. A randomized clinical trial evaluating plasma rich in growth factors (PRGFEndoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012;28:1070-1078.
  80. Vaquerizo V, Plasencia MA, Arribas I. Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: A randomized controlled trial. Arthroscopy. 2013;29:1635-1643.
  81. Raeissadat SA, Rayegani SM, Hassanabadi H. Knee osteoarthritis injection choices: Platelet-rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1-8. 
  82. Higgins LD, Taylor MK, Park D. Reliability and validity of the International Knee Documentation Committee (IKDC) Subjective Knee Form. Joint Bone Spine. 2007;74:594-599. 
  83. Tubach F, Ravaud P, Martin-Mola E. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64:1699-1707.
  84. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring in consistency in meta-analyses. BMJ. 2003;327:557-560. 
  85. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001;45:384-391. 
  86. Cerza F, Carni S, Carcangiu A. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med. 2012;40:2822-2827.
  87. Filardo G, Di Matteo B, Di Martino A, Merli ML, Cenacchi A, Fornasari P, Marcacci M, Kon E. Platelet-rich plasma intra-articular knee injections show no superiority versus visco supplementation: A randomized controlled trial. Am J Sports Med. 2015;43(7):1575-1582.
  88. Gormeli G, Gormeli CA, Ataoglu B, Colak C, Aslanturk O, Ertem K. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: A randomized, double-blind, placebo controlled trial [published online August 2, 2015]. Knee Surg Sports Traumatol Arthrosc. https://doi.org/10.1007/s00167-015-3705-6.
  89. Paterson KL, Nicholls M, Bennell KL, Bates D. Intraarticular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: A double-blind, randomized controlled pilot study. BMC Musculoskelet Disord. 2016;17:67. 
  90. Smith PA. Intra-articular autologous conditioned plasma injections provide safe and efficacious treatment for knee osteoarthritis: An FDA-sanctioned, randomized, double blind, placebo-controlled clinical trial. Am J Sports Med. 2016;44:884-891. 
  91. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, double blind, randomized trial. Am J Sports Med. 2013;41:356-364. 
  92. Martini A. Single Platelet-Rich Plasma Injection for Early Stage of Osteoarthritis of the Knee. Joints. 2017;5:2-6. 
  93. Mastykau AN, Deykalo VP, Balaboshka KB. Platelet-enriched plasma in treatment of posttraumatic chondropathy of the knee joint. Novosti Khirurgii. 2012;20(5):77-81. (In Russ.)
  94. Malanin DA, Novochadov VV, Demkin SA, Demeshchenko MV, Danilov DA. platelet-Rich autologous plasma in the treatment of patients with stage III gonarthrosis. Travmatologiya i ortopediya Rossii. 2014;3(73). (In Russ.)
  95. Lazishvili GD, Egiazaryan KA, Danilov MA. Investigation of the clinical effectiveness of platelet-rich plasma in the treatment of knee osteoarthritis. Department of traumatology and orthopedics. Pirogov Russian national research medical University. M. 2016. (In Russ.).
  96. Meleshkin AV, Zorin DN. Application of PRP-therapy in the treatment of posttraumatic knee joint DOA of 1—2 degrees. 1st international Congress of the Association of reumoortapedics. M., September 28—29, 2017. (In Russ.)
  97. Ryabinin SV, Samoday VG. The use of autologous platelet-rich plasma in the treatment of gonarthritis. Prakticheskaya meditsina. 2018;16(6):190-194. (In Russ.)
  98. Kushnir VA. Comparative analysis of the effectiveness of hyaluronic acid and PRP with hyaluronic acid in rheumatology practice. 2nd international Congress of reumoortopedics. M., 21—22 September 2018. (In Russ.)
  99. Gubar EA, Plekhanov AN, Rinchinov RD, Alekseev SA. Experience of application of platelet-rich autoplasma in the treatment of osteoarthritis of the knee. Vestnik Buryatskogo gosudarstvennogo universiteta. Meditsina i farmatsiya. 2018;3-4:42-45. (In Russ.)
  100. Chesnikov SG, Rosenberg DV, Timoshenko ME, Dedyaev SI. Experience of PRP-therapy in the treatment of patients with gonarthritis. Publishing house: Federal scientific and clinical center for specialized types of medical care and medical technologies of the Federal medical and biological Agency. M. 2018. (In Russ.)
  101. Teplov OV, Teplova YuS, Plakseychuk YuA. Masgutov RF, Masgutova GA, Salikhov RZ, Chekunova MA, Galimov DH. Application of autologous platelet-rich plasma in the treatment of older age group patients with osteoarthritis of the knee joint II—III art. Prakticheskaya meditsina. 2017;8(109):130-132. (In Russ.)
  102. Halimov EV, Savelev SN, Halimov AE, Nuriev RF, Ochkurenko AA. «Possibilities of using platelet-rich autoplasm in the treatment of osteoarthritis of the knee joint». Vestnik travmatologii i ortopedii im. N.N. Priorova. 2016;23-27. (In Russ.)
  103. Gorbatenko AI, Bone N. The use of platelet-rich autoplasma in the treatment of osteoarthritis of the knee joints. Vestnik travmatologii i ortopedii im. N.N. Priorova. 2016;2:40-45. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.